A translational-readiness framework for natural and engineered probiotics

The human microbiome has become a major source of therapeutic candidates, yet clinical translation has progressed far more slowly than mechanistic and preclinical discovery. In this review we ask: what determines whether a microbial therapeutic reaches the clinic? We compare traditional probiotics, next-generation probiotics and engineered live biotherapeutics using representative examples from metabolic disease, oncology and the vaginal microbiome. Together, these examples show that translational success depends less on biological sophistication than on the ability to achieve durable colonization, demonstrate meaningful clinical benefit and satisfy biocontainment and regulatory requirements. We explore the vaginal niche as a case study because it illustrates these challenges particularly well. Its relatively simple microbial community, local delivery and measurable ecological and clinical endpoints allow colonization, activity and recurrence to be assessed together. We integrate these observations into a translational-readiness framework that evaluates microbial therapeutics according to target specificity, colonization durability, biocontainment and safety, demonstrated benefit and regulatory precedent. This framework provides a practical approach for comparing emerging microbial therapeutic candidates and for identifying the factors most likely to accelerate their progression from promising biological discoveries to reliable clinical translation.